Ginkgo Bioworks, Inc. (DNA) Stock: $12 Price Target And Outperform Rating

By Amit Chowdhry ● Mar 3, 2022
  • The shares of Ginkgo Bioworks, Inc. (NYSE: DNA) have received a $12 price target from Cowen. These are the details.

The shares of Ginkgo Bioworks, Inc. (NYSE: DNA) have received a $12 price target from Cowen. And Cowen analyst Steven Mah initiated coverage on Ginkgo Bioworks with an “Outperform” rating.

“Ginkgo democratizes SynBio product R&D and biosecurity surveillance and has a significant lead in scalable genetic engineering, increasing technical success and cost efficiencies via learnings cross-share and premier processes. Attractive Foundry downstream economics derisk as programs scale/diversify. Endemic C19 and new non-C19 TAMs portend durable Biosecurity revs,” wrote Mah in a research note.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.